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Abstract 
Dextran nanobubbles were prepared with a dextran shell and a perfluoropentan core in 
which oxygen was stored. To increase the stability polyvinylpirrolidone was also added to 
the formulation as stabilizing agent. Rhodamine B was used as fluorescent marker to 
obtain fluorescent nanobubbles. The nanobubble formulations showed sizes of about 
500 nm, a negative surface charge and a good capacity of loading oxygen, no hemolytic 
activity or toxic effect on cell lines. The fluorescent labelled nanobubbles could be 
internalized in Vero cells. Oxygen-filled nanobubbles were able to release oxygen in 
different hypoxic solutions at different time after their preparation in in vitro experiments. 
The oxygen release kinetics could be enhanced after nanobubble insonation with 
ultrasound at 2.5 MHz. The oxygen-filled nanobubble formulations might be proposed for 
therapeutic applications in various diseases. 
 
1. Introduction  
Oxygen is one of the key elements in cell metabolism, and its concentration in tissues 
plays an important role in regulating biochemical reactions (Wagner, 2008, Soleymanlou et 
al., 2005). 
Reduced oxygen supply from the arterial blood to cells substantially increases the risk of 
inflammation, infection and scarring, reduces the efficacy of medical treatments and may 
ultimately lead to tissue necrosis. Many medical conditions, such as diabetes, burns, 
bedsores and wounds are related to insufficient supply of oxygen to the tissues; oxygen 
deficiency, together with acidosis, is also the main hallmark of cancerous solid tumors and 
a major factor limiting the effectiveness of radiotherapy (Asimov et al., 2007). These are 
therefore possible fields of application of oxygen-filled nanobubbles besides other 
oxygenation approches (Al-Waili et al., 2005, Overgaard, 1994). Another potential field for 
nanobubbles application is that of anaerobic infections. Anaerobic bacteria grow where 
oxygen is completely, or almost completely, lacking and they can cause infections when a 
normal barrier, such as the skin, gums, or intestinal wall, is damaged due to surgery, 
injury, or disease. The targeted release of oxygen by means of delivery system may be a 
useful adjuvant to antibiotic therapy of anaerobic infections. 
The delivery of oxygen has been examined in various studies (Van Liew and Burkard, 
1996, Burkard and Van Liew, 1994) Hemoglobin-loaded particles (Hb-particles) 
encapsulated within a biodegradable polymer have been prepared for use as oxygen 
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carriers (Zhao et al., 2007). The Hb-particles exhibited oxygen-carrying capacity similar to 
that of native hemoglobin and showed prolonged circulation time after in vivo 
administration in mice. Dextrose albumin microbubbles for oxygen and nitrogen delivery 
have been formulated (Porter et al., 1998) for use as contrast agents. Oxygen-enriched 
lipid-coated perfluorocarbon microbubbles have been prepared for oxygen delivery; these 
oxygen-enriched microbubbles were tested in a model of anemic rats (Unger et al., 2002, 
Unger et al., 2004) and maintained the rat's survival at very low hematocrit levels. 
Oxygen-filled chitosan microbubbles showed to act as an efficient oxygen delivery system 
(Cavalli et al., 2009). The in vitro oxygen release from the chitosan microbubbles in 
hypoxic media was previously evaluated before and after ultrasound (US) sonication, and 
the results supported the hypothesis that US enhances gas delivery. Preliminary 
investigations on the biological effect of such oxygen release on the cellular activity were 
also undertaken, and an effect on the expression of Hypoxia Inducible Factor-1α (HIF-1) 
from hypoxic human choriocarcinoma cells after oxygen-filled microbubble delivery was 
demonstrated (Bisazza et al., 2008). 
The aim of the present study was to develop a new bubble formulation in the nanometer 
size range for use as an innovative oxygen-delivery system. 
New formulations were developed, consisting of nanobubbles with a dextran coating and 
bubble stabilization was improved, both by adding a poorly soluble gas (perfluoropentan) 
to the core and (Lundgren et al., 2006) by adding polyvinylpyrrolidone (PVP) to the shell. 
The resulting nanobubbles were characterized by their sizes, chemical properties, oxygen 
release efficiency, biocompatibility and cellular uptake, in view of their possible 
applications in treating chronic wounds and anaerobic infections. 
 
2. Materials and methods  
2.1. Materials  
Ethanol 96° was from Carlo Erba (Milan, I). Epikuron® 200 (soya phosphatidylcholine 95%) 
was a kind gift from Degussa (Hamburg, D). Palmitic acid, perfluoropentan, dextran 
sulphate sodium salt (Mw = 100,000), polyvinylpyrrolidone (PVP) (Mw = 24,000) were from 
Fluka (Buchs, CH). Rhodamine B and diethylamino-ethyl-dextran hydrocloride (DEAE) (Mw 
= 500,000) were from Sigma Aldrich (St. Louis, USA). Ultra-pure water was obtained using 
a system 1-800 Milli-Q (Millipore, F). Dulbecco's modified Eagle's medium (DMEM), fetal 
calf serum and antibiotics for cell culture were from Gibco/BRL (Gaithersburg, MD, USA). 
2.2. Preparation of oxygen-filled nanobubbles  
An ethanol solution containing Epikuron® 200 (1%, w/v) and palmitic acid (0.3%, w/v) was 
added to perfluoropentan and ultra-pure water under stirring. The solution was saturated 
with oxygen up to a gas concentration of 35 mg/l. A 2.7% (w/v) dextran solution (Mw 
dextran = 100,000) was added drop-wise while the mixture was homogenized, using a 
high-shear homogenizer (Ultraturrax, Germany) for 2 min at 13,000 rpm and continuing the 
oxygen purge, in the presence (formulation B) or absence (formulation A) of 5% (w/v) 
polyvinylpyrrolidone (PVP) solution as stabilizing agent. 
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Rhodamine B was used as fluorescent marker to prepare fluorescent labelled 
nanobubbles (Visser et al., 1999). For whose preparation procedure was similar to the 
above described for formulation A. Rhodamine B (0.002%, w/v) was added drop-wise 
during the homogeneization step to a 2.7% (w/v) diethylamino-ethyl-dextran hydrocloride 
(DEAE) solution. Finally a 2.7% (w/v) dextran solution was added drop-wise under stirring. 
The composition of the nanobubbles is reported in Table 1. 
Table 1: Composition of the three formulations.
Components Formulation A (%, w/v) Formulation B (%, w/v) Formulation C (%, w/v) 
Palmitic acid 0.02 0.02 0.01 
Epikuron® 200 0.02 0.05 0.05 
Perfluoropentan 7.02 6.70 6.58 
Filtered water 88.53 88.80 89.06 
Dextran 0.17 0.16 0.16 
Pvp – 0.25 – 
Ethanol 4.24 4.02 3.98 
Deae + rhodamine B – – 0.16 
 
 
 
2.3. Characterization of the nanobubble formulations  
2.3.1. Size, particle size distribution and zeta potential determination  
The average diameters and polydispersity indices of the nanobubble formulations were 
determined by photocorrelation spectroscopy (PCS) using a 90 Plus instrument 
(Brookhaven, NY, USA) at a fixed angle of 90° and a temperature of 25 °C. Each value 
reported is the average of 10 measurements of 3 different formulations. The polydispersity 
index indicates the size distribution within a nanobubble population. The electrophoretic 
mobility and zeta potential of the formulations were determined using a 90 Plus instrument 
(Brookhaven, NY, USA). For zeta potential determination, samples of the formulation were 
placed in the electrophoretic cell, where an electric field of about 15 V/cm was applied. 
Each sample was analyzed at least in triplicate. The electrophoretic mobility measured 
was converted into zeta potential using the Smoluchowsky equation (Sze et al., 2003).
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2.3.2. Morphological analysis  
The morphology of nanobubble formulations was determined by Transmission Electron 
Microscopy (TEM). TEM analysis was carried out using a Philips CM10 instrument 
(Eindoven, NL). The nanobubble preparations were dropped onto a Formwar-coated 
copper grid and air-dried before observation. The morphology of fluorescent nanobubbles 
was determined by fluorescent microscopy employing a Leitz (Germany) instrument. 
2.3.3. Stability of the formulations  
To determine the stability of formulations A and B upon dilution, the nanobubble 
fomulations were diluted 1:10 (v/v) with saline solution (0.9% NaCl) and with rat plasma 
solution (plasma:phosphate buffer pH 7.4, 1:4, v/v) at 25 and 37 °C. After 5, 10, 15 min, 1 
and 24 h of incubation their size, size distribution and zeta potential values were measured 
by photocorrelation spectroscopy (PCS) using a 90 Plus instrument (Brookhaven, NY, 
USA) at a fixed angle of 90°. 
The formulation stability stored at 25 °C was evaluated over time, up to 24 h, determining 
the oxygen release rate, the morphology and the sizes of nanobubbles by TEM and by 
PCS, respectively. 
2.4. Biocompatibility assessment  
2.4.1. Determination of hemolytic activity  
The hemolytic activity of formulations A and B was evaluated on human blood. Different 
percentages (v/v) (1.5%, 2.9%, 5.6%, 8.1%, 9.8%) of nanobubble formulations were added 
to a suspension of erythrocytes (30%, v/v) in phosphate buffer pH 7.4. A solution 
containing only a suspension (30%, v/v) of erythrocytes in phosphate buffer pH 7.4 was 
used as blank. A blank containing an excess of ammonium chloride was used to obtain 
complete hemolysis as hemolytic control. 
After 90 min of incubation at 37 °C the samples were centrifuged at 2000 rpm for 10 min 
and the supernatant was analyzed using a Lambda 2 Perkin-Elmer spectrophotometer at a 
wavelength of 543 nm. The percentage of hemolysis was calculated versus the 100% 
hemolysis control. 
2.4.2. Cell viability assay  
To test the effect of formulations A and B on cell viability, African green monkey 
fibroblastoid kidney cells (Vero) were seeded at a density of 1 × 104 /well in 96-well plates 
in DMEM supplemented with 10% of heat-inactivated fetal calf serum and antibiotics. 
After 24 h they were incubated with 5 and 10 mg of nanobubbles obtained by appropriate 
dilutions of the formulations or left untreated. After 48 h cell viability was determined by the 
CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA) according to the 
manufacturer's instructions. The effect on cell viability of each formulation at different 
concentrations was expressed as a percentage, by comparing treated cells with cells 
incubated with culture medium alone. For the assay, the experiments were performed in 
triplicate.
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2.5. In vitro determination of oxygen release  
The oxygen concentration of two 0.9% NaCl (saline) solutions, sealed into two vials, was 
reduced respectively to 0.4 mg/l (severe hypoxia) and to 4 mg/l (moderate hypoxia) with a 
N2 purge, in order to mimic hypoxic conditions. A series of experiments was carried out 5, 
30, 60, 180 min and 24 h after the preparation of the formulations to investigate the 
oxygen release kinetics over time. Then 3 ml of oxygen-filled nanobubbles were 
introduced into 20 ml of each saline solution, and the oxygen release kinetic was 
monitored for 10 min using an oxymeter (Portamess 913 OXY, Knick). Before each 
experiment the oxymeter was calibrated in air, after waiting for stable temperature and 
humidity conditions to be re-established. 
2.6. In vitro determination of oxygen release in the presence of ultrasound  
To study the effect of ultrasound (US) on oxygen release from nanobubbles, a US probe 
with an oscillation frequency of 2.5 ± 0.1 MHz and an average acoustic pression 
distribution value of 2.4 ± 0.2 MPa (nominal frequency: 50 Hz; and nominal power: 30 W) 
was used, combined with a peculiar apparatus consisting of two compartments separated 
by a silicon membrane. 70 ml of saline solution and 10 ml of oxygen-filled nanobubbles 
were placed in the first compartment; 20 ml of saline hypoxic solution (0.4 mg/l) were 
placed in the second compartment. The concentration of oxygen in the hypoxic 
compartment was monitored for 10 min in the presence of US after 30 min from 
nanobubbles preparation. To monitor the oxygen concentration, the transducer of the 
device was held in a fixed position, within the donor compartment. All the experiments 
were performed in triplicate. 
2.7. Evaluation of cellular uptake through confocal laser scanning microscopy  
African green monkey fibroblastoid kidney cells (Vero) were grown as monolayers in 
DMEM supplemented with 10% of heat-inactivated fetal calf serum and antibiotics. 
Exponentially growing Vero cells were plated and cultured overnight in 24-well plates on 
glass coverslips; the cell monolayers were incubated with appropriated dilutions of 
rhodamine-labeled nanobubbles for 1 h and then extensively washed with PBS for 
observation of live cells. Confocal sections were taken on an inverted Zeiss LSM510 
fluorescence microscope. 
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3. Results  
The average diameter, polydispersity index, zeta potential values of oxygen-filled 
nanobubbles, plus the pH values of their aqueous suspensions, are reported in Table 2. 
  
 
Table 2: Physico-chemical characteristics of the three formulations.
Formulation Average diameter ± S.D. (nm) Polydispersity index PZ ± S.D. (mV) pH 
Formulation A 550 ± 30 0.20 −41 ± 1 6.40 
Formulation B 410 ± 5 0.18 −23 ± 2 6.30 
Formulation C 520 ± 10 0.25 −37 ± 1 7.40 
 
The sizes of the three nanobubble formulations were below 1 μm, with a rather uniform 
size distribution. The presence of the fluorescent marker did not affect the diameter of 
nanobubbles while the presence of PVP formed smaller nanobubbles with a lower 
polydispersity index. PVP acts as stabilizer agent on the nanobubble surface forming a 
hydrophylic coating which might impart “stealth-like” properties in view of in vivo 
administration. 
The surface of the nanobubbles showed a negative charge that was sufficiently high to 
prevent nanobubble aggregation. The addition of PVP in the nanobubble formulation 
decreased the zeta potential and thus confirmed the presence of PVP on the nanobubble 
surface. TEM analyses showed the spherical shape of nanobubbles confirming their sizes. 
The TEM image of oxygen-filled formulation A is reported in Fig. 1. The photomicrographs 
evidenced a clearly visible dextran shell of about 30 nm. 
 
 
Fig. 1: TEM image of nanobubble formulation A (magnification 27,500×).
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The oxygen-filled nanobubbles proved to be stable after dilution both in saline solution and 
in plasma, after incubation at 25 and 37 °C, as evidenced by TEM and photocorrelation 
spectroscopy analyses. As shown in Fig. 2 A nanobubble average diameters did not 
change upon dilution in plasma at 25 °C and the stability of the two formulations in the 
absence or in the presence of PVP is similar over time. At 37 °C PVP increased the 
nanobubble stability, indeed the diameters of formulation B are maintained over time (Fig. 
2 B). 
 
 
Fig. 2: Stability upon dilution of oxygen-filled nanobubbles over time: (A) in plasma 
at 25 °C; (B) in plasma at 37 °C. 
 
 
The structure stability at 25 °C was confirmed by TEM, 24 h after the nanobubble 
preparation. The analyses showed that the spherical shape and sizes of the nanobubble 
formulations did not change 24 h after their preparation (data not shown). 
Formulations A and B showed no toxicity toward Vero cells after 48 h of incubation at each 
concentration tested (5 and 10 mg) as shown in Fig. 3. 
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Fig. 3: Effect of formulations A and B on viability of Vero cells as a function of the 
concentration at 48 h post-treatment. Each point represents the mean ± S.D. (n = 3). 
 
Moreover the three nanobubble formulations demonstrated no hemolytic activity tested on 
in vitro red blood cells after 90 min incubation at 37 °C. 
The oxygen concentration of the two types of hypoxic solutions increased markedly over 
time after the injection of the oxygen-filled nanobubbles. The nanobubbles showed the 
capacity of oxygen release either immediately after their preparation either over time. The 
oxygen increase produced by nanobubbles 5 min after their preparation is reported in Fig. 
4. A greater amount of oxygen was released in severe hypoxic conditions (0.4 mg/l) than 
in moderate hypoxic conditions; producing an increase in the oxygen concentration of 
about 8-fold after 10 min. 
 
 
 
Fig. 4: Oxygen concentration in severe (0.4 mg/l) and moderate (4 mg/l) hypoxic 
condition after the injection of nanobubble formulation 5 min after their preparation. 
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The oxygen release kinetics obtained 30 min, 1 h and 3 h after the preparation of the 
formulations are reported in Fig. 5. The oxygen release profiles did not change up to 3 h 
after preparation showing the stability of the formulations. Starting from severe hypoxic 
conditions, the oxygen release kinetics are slower in the presence of the PVP probably 
due to the greater thickness of the shell. Indeed the oxygen concentration reached about 
3.7 mg/l in 2 min for formulation A and the same value in 15 min for PVP-stabilized 
formulation B. A slower oxygen release kinetics in the presence of PVP were also 
observed after 24 h from the nanobubble preparation. 
 
 
 
 
Fig. 5: Oxygen concentration after the injection of nanobubble formulation 30 min, 1 h and 3 h after 
their preparation. (A) Formulation A severe hypoxia (0.4 mg/l), (B) formulation B severe hypoxia (0.4 
mg/l), (C) formulation A moderate hypoxia (4 mg/l), and (D) formulation B moderate hypoxia (4 mg/l).
 
US favored oxygen delivery from the oxygen-filled nanobubbles and the release kinetics 
were faster than those in the absence of US. Fig. 6 shows the oxygen delivery from 
formulation A nanobubbles through a silicon membrane in the presence of US. The 
oxygen concentration in the receiving compartment was “incremented” by as much as 
133% in the presence of US. A similar kinetic behaviour was obtained with the PVP 
stabilized nanobubble formulation. 
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Fig. 6: Oxygen delivery from nanobubble formulation A through a silicon membrane in 
the presence and absence of US. 
 
The cellular uptake of fluorescent-labeled nanobubbles was monitored through confocal 
laser scanning microscopy, on living unfixed cells to avoid artifactual results due to cell 
fixation protocols. The results demonstrate that after 1 h the nanobubbles are internalized 
in the cells, and show a diffuse cytoplasmic distribution (Fig. 7) without cytotoxic effects. 
 
 
 
Fig. 7: Cellular uptake of oxygen-filled nanobubbles. Vero cells were incubated for 1 h with the 
rhodamine-labeled nanobubbles (50 μl) and then analyzed by confocal laser scanning microscopy 
without fixation. The figure shows phase-contrast (right panel) and immunofluorescence (left 
panel) images of the same microscopic field. The nanobubbles are internalized with diffuse 
cytoplasmic distribution. 
 
This result indicates that nanobubbles might be capable of delivering a gas or a drug 
directly inside the cells.
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4. Discussion  
In this study oxygen-filled nanobubbles were prepared using perfluoropentan as core and 
dextran sulphate, a polysaccharide polymer, as shell. The biocompatibility of dextran-
based formulations have been extensively studied (Bos et al., 2005, De Groot et al., 2001). 
Recently dextran-based hydrogels have been studied as matrices in tissue engineering; no 
sign of inflammation was detected in in vivo experiments (Möller et al., 2007). 
The two types of nanobubble formulations as well as the fluorescent one, showed an 
average diameters lower than 1 μm, a spherical morphology with a core 
-shell structure and a negative charge high enough to avoid nanobubble aggregation; 
consequently they could maintain their structure and small dimension over time. The 
nanobubble sizes and stability are important properties in view of their potential in vivo 
administration. PVP was added to the formulation to increase nanobubble stability. The 
choice of PVP was due to its long-standing and safety in biomedical/pharmaceutical 
applications. PVP is an excipient reported in USP 28 and in other Pharmacopeia as 
suspending, stabilizing or viscosity-increasing agent admitted for parenteral formulations. 
PVP solutions may also be used as coating agent. The PVP-stabilized nanobubbles 
(formulation B) maintained their sizes after dilution with plasma and after incubation at 37 
°C. Moreover the size of PVP nanobubbles did not increase over time showing their 
greater physical stability than formulation A. 
The nanobubble structure of the two formulations upon dilution is maintained and it is 
stable up to 24 h. In heterogeneous systems, it can sometimes happen the formation of a 
small flocculate after dilution, that could give a precipitate over time. This effect should be 
favoured by the enhancement of temperature that increase the particle kinetics and the 
convective movements of particles. The presence of PVP as stabilizing agent could avoid 
this precipitation phenomena. Moreover, the addition of PVP to the formulation did not 
affect cell viability. 
The nanobubbles prepared had a good oxygen-loading capacity due to the presence of 
gas core. Perfluoropentan gas can favor oxygen entrapment. On a volume basis, Van Liew 
has previously shown that gaseous perfluorocarbon compounds may deliver more oxygen 
than liquid perfluorocarbons (Van Liew and Burkard, 1997). The dextran nanobubbles 
were able to release oxygen in hypoxic condition. Oxygen could diffuse into the external 
water phase quickly when the nanobubble formulations are brought into contact with a 
hypoxic medium. The oxygen was released in greater extent in severe hypoxic condition 
(oxygen concentration 0.4 mg/l) than in moderate hypoxic condition (oxygen concentration 
4 mg/l). A slower release profile was observed in the presence of PVP in hypoxic 
condition. Ultrasound (US) technology in medicine has developed rapidly over the last 
decades particularly it's use in diagnostic imaging (Sboros, 2008, Pitt, 2003, Giustetto et 
al., 2008, Rapoport et al., 2004, Tran et al., 2007). 
Nanobubbles can also be cavitated by US energy to increase oxygen release kinetics, 
which might be useful for possible local site-specific delivery. Ultrasound did not change 
physical properties of nanobubbles after 10 min of insonation. Hemolitic activity and cell 
studies showed the biocompatibility of the nanobubble formulations and their capacity to 
be internalized in the cell without producing toxic effects. 
12 
 
Dextran nanobubbles might be proposed for the delivery of oxygen, and thus might 
represent a new class of therapeutic systems for various diseases. Particularly the 
targeted delivery of oxygen by means of US and microbubbles and US may be exploited 
as an adjuvant to antibiotics whenever anaerobic infection is suspected. 
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